Abstract.
Critically ill patients routinely receive H2 antagonists for stress ulcer prophylaxis while at risk for gastrointestinal bleeding. In these patients it is often difficult to assess accurately the cause of adverse effects such as thrombocytopenia. We evaluate the literature to better define thrombocytopenia related to H2 antagonist administration and discuss mechanism, potential as a risk factor and case reports describing the severity and duration of thrombocytopenia.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Electronic Publication
Rights and permissions
About this article
Cite this article
Wade, E.E., Rebuck, J.A., Healey, M.A. et al. H2 Antagonist-induced thrombocytopenia: is this a real phenomenon?. Intensive Care Med 28, 459–465 (2002). https://doi.org/10.1007/s00134-002-1233-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00134-002-1233-6